

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE BY SECURED PARTY

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Credit Suisse AG		01/31/2011	bank: SWITZERLAND

RECEIVING PARTY DATA

Name:	Monarch Pharmaceuticals, Inc.
Street Address:	501 Fifth Street
City:	Bristol
State/Country:	TENNESSEE
Postal Code:	37620
Entity Type:	CORPORATION: TENNESSEE

PROPERTY NUMBERS Total: 13

Property Type	Number	Word Mark
Registration Number:	2029430	ACCUDOSE
Registration Number:	3130490	ACCUDOSE
Registration Number:	0616775	CORTISPORIN
Registration Number:	0581264	KEMADRIN
Registration Number:	1350257	
Registration Number:	1808767	MENEST
Registration Number:	1101912	NUCOFED
Registration Number:	1498288	PEDIOTIC
Registration Number:	0806889	PROLOPRIM
Registration Number:	0735573	QUIBRON
Registration Number:	0904178	SEPTRA
Registration Number:	1216341	THALITONE
Registration Number:	1018684	VIROPTIC

CORRESPONDENCE DATA

900182917

**TRADEMARK
 REEL: 004465 FRAME: 0714**

CH \$340.00 2029430

Fax Number: (202)778-5299
Correspondence will be sent via US Mail when the fax attempt is unsuccessful.
Phone: 202.662.5299
Email: trademarks@cov.com
Correspondent Name: Kathleen T. Gallagher-Duff, Esq.
Address Line 1: 1201 Pennsylvania Avenue, N.W.
Address Line 4: Washington, DISTRICT OF COLUMBIA 20004

ATTORNEY DOCKET NUMBER:	029459.00030
NAME OF SUBMITTER:	Cheryl L. Fountain/Paralegal Specialist
Signature:	/cheryllfountain/
Date:	02/02/2011

Total Attachments: 3
source=Monarch TM Release#page1.tif
source=Monarch TM Release#page2.tif
source=Monarch TM Release#page3.tif

Release of Security Interest in Trademarks

January 31, 2011

WHEREAS, KING PHARMACEUTICALS, INC., a Tennessee corporation, as Borrower, certain of its subsidiaries, as Guarantors, and CREDIT SUISSE AG (“**Credit Suisse**”), in its capacity as Collateral Agent for the Secured Parties (as each term is defined in the GCA (as defined below)), entered into that certain Guarantee and Collateral Agreement (the “**GCA**”) dated as of May 11, 2010;

WHEREAS, pursuant to the GCA, Credit Suisse and Monarch Pharmaceuticals, Inc., a Tennessee corporation (the “**Assignee**”), entered into that certain Trademark Security Agreement dated May 11, 2010 and recorded with the United States Patent and Trademark Office on May 13, 2010 on Reel No. 4205, Frame No. 0676 (the “**Trademark Security Agreement**”);

WHEREAS, under the Trademark Security Agreement, the Assignee granted to Credit Suisse a security interest in certain Trademark Collateral (as defined in the Trademark Security Agreement), including those items set forth on Schedule 1 hereto (collectively, the “**Released Trademark Collateral**”);

WHEREAS, the parties agree and acknowledge that the foregoing United States Patent and Trademark Office assignment record may list Credit Suisse AG in a capacity other than Collateral Agent, and that the security interest was granted to, and this release is correctly made by, Credit Suisse, as Collateral Agent; and

WHEREAS, Credit Suisse desires to release the security interest granted by the Assignee under the Trademark Security Agreement in the Released Trademark Collateral.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Credit Suisse, as Collateral Agent for the Secured Parties, does hereby unconditionally, irrevocably and absolutely terminate, release, extinguish and forever discharge the security interest granted under the Trademark Security Agreement in the Released Trademark Collateral, together with all of the goodwill of the business connected with the use of, or symbolized by, such Released Trademark Collateral, and hereby unconditionally, irrevocably and absolutely assigns, transfers and conveys to the Assignee all right, title and interest of Credit Suisse in, to and under such Released Trademark Collateral and such goodwill granted under the Trademark Security Agreement. This Release of Security Interest in Trademarks shall be binding upon Credit Suisse’s legal representatives, assigns and successors, and upon the Secured Parties and their legal representatives, assigns and successors. Credit Suisse also hereby authorizes, and requests, the Director of the United States Patent and Trademark Office or his delegate to record this Release of Security Interest in Trademarks against the Released Trademark Collateral.


[signature page to follow]

IN WITNESS WHEREOF, Credit Suisse has caused this Release of Security Interest in Trademarks to be duly executed by its officers thereunto duly authorized as of the day and year first above written.

CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH

By: 

Name: DOREEN BARR
Title: DIRECTOR

By: 

Name: VIPUL DHADDA
Title: ASSOCIATE

[signature page – Monarch Pharmaceuticals, Inc. trademark release]

Schedule 1

MONARCH PHARMACEUTICALS, INC.

U.S. TRADEMARK REGISTRATIONS

Trademark	Registration No.	Registration Date
ACCUDOSE	2029430	January 14, 1997
ACCUDOSE	3130490	August 15, 2006
CORTISPORIN	616775	November 29, 1955
KEMADRIN (Stylized)	581264	October 20, 1953
Kidney Shape and Design	1350257	July 23, 1985
MENEST	1808767	December 7, 1993
NUCOFED	1101912	September 12, 1978
PEDIOTIC	1498288	August 2, 1988
PROLOPRIM	806889	April 12, 1966
QUIBRON	735573	August 7, 1962
SEPTRA	904178	December 15, 1970
THALITONE	1216341	November 16, 1982
VIROPTIC	1018684	August 26, 1975

U.S. TRADEMARK APPLICATIONS

None.

TRADEMARK LICENSES

Name of Agreement	Parties (Licensor/Licensee)	Date of Agreement	Subject Matter
Agreement for Purchase and Sale of Assets Relating to Neosporin and Polysporin	Glaxo-Wellcome / Monarch Pharmaceuticals, Inc.	November 14, 1997	Neosporin and Polysporin